Essiac ® is an herbal compound that has been widely used as a dietary supplement for health and immune system support, as well as a homeopathic cancer treatment. Despite multiple studies aiming to demonstrate its touted benefits, the results have been inconclusive. Some studies have shown Essiac ® to impart gastroenterological protection, combat reactive oxygen species (ROS), increase immune cell subsets, and reduce in vitro cancer cell numbers, while other studies have not been able to show reduced cancer load in vivo. Therefore, in this study using the fully-prepared proprietary blend, Essiac ® Liquid Herbal Extract (LHE), we thoroughly explored its health benefits using the nematode animal model, Caenorhabditis elegans (C. elegans), as well as assessed its antiproliferative abilities against three non-adherent (myeloma, lymphoma, and leukemia) and two adherent tumor forming (breast and prostate) cancer cell lines. Our findings show that when C. elegans were exposed to the recommended dosage of Essiac ® LHE, there was an increase in their overall lifespan, and an increase in their ability to withstand oxidative stress induced mortality when challenged. Additionally, our work demonstrated that a 24% exposure of Essiac ® LHE induced a significant decrease in cell viability and proliferation within all five cancer cell lines (RPMI 8226, Jurkat, CML, LNCaP, and MCF7). Furthermore, our results indicate that the anti-proliferative effects of Essiac ® LHE are not being mediated through the induction of intrinsic apoptosis, but through an alternative cellular mechanism. Taken together, these in vitro and in vivo findings lend support to the overall health benefits and antiproliferative abilities of Essiac ® LHE.